#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

# FORM 8-K

# CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

#### November 9, 2023

Date of Report (Date of earliest event reported)

# **DENTSPLY SIRONA Inc.**

(Exact name of registrant as specified in its charter)

Delaware0-1621139-1434669(State or other jurisdiction of incorporation or organization)(Commission File Number)(I.R.S. Employer Identification No.)

 13320 Ballantyne Corporate Place.
 Charlotte
 North Carolina
 28277-3607

 (Address of Principal Executive Offices)
 (Zip Code)

(844) 848-0137

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.01 per share	XRAY	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

#### Item 7.01. Regulation FD Disclosure

On November 9, 2023, as part of its investor day, DENTSPLY SIRONA Inc. (the "Company") issued the attached press release (the "Press Release") describing certain information to be presented. During the event, representatives of the Company will present the materials attached as Exhibit 99.2 which, among other things, introduce the Company's three-year financial targets and provide an update on the Company's 2023 financial outlook. A copy of the Press Release and presentation are being furnished as Exhibit 99.1 and Exhibit 99.2 to this report.

Investors and other interested parties will be able to access a live webcast and webcast replay by visiting the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com.

The information furnished pursuant to Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

#### Item 9.01. Financial Statements and Exhibits

#### (d) Exhibits:

- DENTSPLY SIRONA Inc. press release, dated November 9, 2023, as referenced in Item 7.01
- 99.2 104 DENTSPLY SIRONA Inc. 2023 Investor Day Presentation, dated November 9, 2023, as referenced in Item 7.01 Cover Page Interactive Data File (embedded within the Inline XBRL Document)

# SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DENTSPLY SIRONA Inc.

Ву:

/s/ Richard C. Rosenzweig
Richard C. Rosenzweig
Senior Vice President, Corporate Development,
General Counsel and Secretary

Date: November 9, 2023



# Dentsply Sirona to Host its Investor Day and Introduce Three-Year Financial Targets

**Charlotte, N.C., November 9, 2023 -** DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) will host its Investor Day today at the Company's headquarters in Charlotte, N.C. The event will begin at 8:30 AM ET.

The event will include presentations from members of its executive management team, live Q&A, and panel discussions with commercial leaders and customers. As part of the event, the Company will introduce three-year financial targets including details of its plan to achieve adjusted EPS of \$3.00 in 2026.

The Company is also announcing that its Board of Directors has authorized an additional \$1 billion share repurchase program.

Investors and other interested parties will be able to access a live webcast, webcast replay, and a presentation related to the event by visiting the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com. The Company does not provide forward-looking estimates on a GAAP basis, as certain information is not available without unreasonable effort and cannot be reasonably estimated.

#### **About Dentsply Sirona**

Dentsply Sirona is the world's largest manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering, including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona's products provide innovative, high-quality, and effective solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona's headquarters are located in Charlotte, North Carolina. The Company's shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

#### **Contact Information:**

Investors:
Andrea Daley
Vice President, Investor Relations
+1-704-805-1293
InvestorRelations@dentsplysirona.com

Press:

Marion Par-Weixlberger Vice President, Public Relations & Corporate Communications +43 676 848414588 marion.par-weixlberger@dentsplysirona.com

#### Forward-Looking Statements and Associated Risks

This Press Release contains statements that do not directly and exclusively relate to historical facts which constitute forward-looking statements, including, statements and projections concerning, among other things, the expected timing, benefits and costs associated with the Company's restructuring plan described in this Press Release. The Company's forward-looking statements represent current expectations and beliefs and involve risks and uncertainties. Actual results may differ significantly from those projected or suggested in any forward-looking statements and no assurance can be given that the results described in such forward-looking statements will be achieved. Investors are cautioned not to place undue reliance on such forward-looking statements which speak only as of the date they are made. The forward-looking statements are subject to numerous assumptions, risks and uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control. The Company does not undertake any obligation to release publicly any revisions to such forwardlooking statements to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events. Any number of factors could cause the Company's actual results to differ materially from those contemplated by any forward-looking statements, including, but not limited to, the risks associated with the following: the Company's ability to remain profitable in a very competitive marketplace, which depends upon the Company's ability to differentiate its products and services from those of competitors; the Company's failure to realize assumptions and projections which may result in the need to record additional impairment charges; the effect of changes to the Company's distribution channels for its products and the failure of significant distributors of the Company to effectively manage their inventories; the Company's ability to control costs and failure to realize expected benefits of cost reduction and restructuring efforts and the Company's failure to anticipate and appropriately adapt to changes or trends within the rapidly changing dental industry. Investors should carefully consider these and other relevant factors, including those risk factors in Part I, Item 1A, ("Risk Factors") in the Company's most recent Form 10-K, including any amendments thereto, and any updating information which may be contained in the Company's other filings with the SEC, when reviewing any forward-looking statement. The Company notes these factors for investors as permitted under the Private Securities Litigation Reform Act of 1995. Investors should understand it is impossible to predict or identify all such factors or risks. As such, you should not consider either the foregoing lists, or the risks identified in the Company's SEC filings, to be a complete discussion of all potential risks or uncertainties.

#### **Non-GAAP Financial Measures**

In addition to results determined in accordance with U.S. generally accepted accounting principles ("US GAAP") the Company provides certain measures in this press release, described below, which are not calculated in accordance with US GAAP and therefore represent Non-GAAP measures. These Non-GAAP measures may differ from those used by other companies and should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP. These Non-GAAP measures are used by the Company to measure its performance and may differ from those used by other companies.

Management believes that these Non-GAAP measures are helpful as they provide a measure of the results of operations, and are frequently used by investors and analysts to evaluate the Company's performance exclusive of certain items that impact the comparability of results from period to period, and which may not be indicative of past or future performance of the Company.

Organic Sales

The Company defines "organic sales" as the reported net sales adjusted for: (1) net sales from acquired businesses recorded prior to the first anniversary of the acquisition; (2) net sales attributable to disposed businesses or discontinued product lines in both the current and prior year periods; and (3) the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period's foreign currency exchange rates.

#### Adjusted Operating Income and Margin

Adjusted operating income is computed by excluding the following items from operating income (loss) as reported in accordance with US GAAP:

- (1) Business combination related costs and fair value adjustments. These adjustments include costs related to consummating and integrating acquired businesses, as well as net gains and losses related to the disposed businesses. In addition, this category includes the post-acquisition roll-off of fair value adjustments recorded related to business combinations, except for amortization expense of purchased intangible assets noted below. Although the Company is regularly engaged in activities to find and act on opportunities for strategic growth and enhancement of product offerings, the costs associated with these activities may vary significantly between periods based on the timing, size and complexity of acquisitions and as such may not be indicative of past and future performance of the Company.
- (2) Restructuring related charges and other costs. These adjustments include costs related to the implementation of restructuring initiatives, including but not limited to, severance costs, facility closure costs, and lease and contract termination costs, as well as related professional service costs associated with these restructuring initiatives and global transformation activity. The Company is continually seeking to take actions that could enhance its efficiency; consequently, restructuring charges may recur but are subject to significant fluctuations from period to period due to the varying levels of restructuring activity, and as such may not be indicative of past and future performance of the Company. Other costs include charges related to legal settlements, executive separation costs, and changes in accounting principle recorded within the period. This category also includes costs related to the recent investigations, related ongoing legal matters and associated remediation activities which primarily include legal, accounting and other professional service fees, as well as turnover and other employee-related costs.
- (3) Goodwill and intangible asset impairments. These adjustments include charges related to goodwill and intangible asset impairments.
- (4) Amortization of purchased intangible assets. This adjustment excludes the periodic amortization expense related to purchased intangible assets, which are recorded at fair value. Although these costs contribute to revenue generation and will recur in future periods, their amounts are significantly impacted by the timing and size of acquisitions, and as such may not be indicative of the future performance of the Company.
- (5) Fair value and credit risk adjustments. These adjustments include the non-cash mark-to-market changes in fair value associated with pension assets and obligations, and equity-method investments. Although these adjustments are recurring in nature, they are subject to

significant fluctuations from period to period due to changes in the underlying assumptions and market conditions. The non-service component of pension expense is a recurring item, however it is subject to significant fluctuations from period to period due to changes in actuarial assumptions, interest rates, plan changes, settlements, curtailments, and other changes in facts and circumstances. As such, these items may not be indicative of past and future performance of the Company.

Adjusted operating income margin is calculated by dividing adjusted gross profit by net sales.

#### Adjusted Gross Profit and Margin

Adjusted gross profit is computed by excluding from gross profit the impact any of the above adjustments that affect either sales or cost of sales, which are primarily comprised of certain portions of intangible asset amortization expense.

Adjusted gross profit margin is calculated by dividing adjusted gross profit by net sales.

#### Adjusted Net Income (Loss)

Adjusted net income (loss) consists of net income (loss) as reported in accordance with US GAAP, adjusted to exclude the items identified above, as well as the related income tax impacts of those items. Additionally, net income is adjusted for other tax-related adjustments such as: discrete adjustments to valuation allowances and other uncertain tax positions, final settlement of income tax audits, discrete tax items resulting from the implementation of restructuring initiatives and the windfall or shortfall relating to exercise of employee share-based compensation, any difference between the interim and annual effective tax rate, and adjustments relating to prior periods.

These adjustments are irregular in timing, and the variability in amounts may not be indicative of past and future performance of the Company and therefore are excluded for comparability purposes.

#### Adjusted EBITDA and Margin

In addition to the adjustments described above in arriving at adjusted net income, adjusted EBITDA is computed by further excluding any remaining interest expense, net, income tax expense, depreciation and amortization.

Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by net sales.

#### Adjusted Earnings (Loss) Per Diluted Share

Adjusted earnings (loss) (EPS) per diluted share is computed by dividing adjusted earnings (loss) attributable to Dentsply Sirona shareholders by the diluted weighted average number of common shares outstanding.

#### Adjusted Free Cash Flow and Conversion


The Company defines adjusted free cash flow as net cash provided by operating activities minus capital expenditures during the same period, and adjusted free cash flow conversion is defined as

adjusted free cash flow divided by adjusted net income (loss). Management believes this Non-GAAP measure is important for use in evaluating the Company's financial performance as it measures our ability to efficiently generate cash from our business operations relative to earnings. It should be considered in addition to, rather than as a substitute for, net income (loss) as a measure of our performance or net cash provided by operating activities as a measure of our liquidity.



# 2023 Investor Day

November 9, 2023 Charlotte, NC





# Welcome and Opening Remarks

Andrea Daley VP, Investor Relations



November 9, 2023

# Forward-Looking Statements and Associated Risks

Forward-Looking Statements that do not directly and exclusively relate to historical facts which constitute forward-looking statements, including, statements and projections concerning, among other things, the expected timing, benefits and costs associated with the Company's restructuring plan described in this presentation. The Company's forward-looking statements represent current expectations and beliefs and involve risks and uncertainties. Actual results may differ significantly from those projected or suggested in any forward-looking statements and no assurance can be given that the results described in such forward-looking statements will be achieved. Investors are cautioned not to place undue reliance on such forward-looking statements with speak only as of the date they are made. The forward-looking statements are subject to numerous assumptions, risks and uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control. The Company does not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances occurring after the date hereof or to reflect the occurrence of unanticipated events. Any number of factors could cause the Company's actual results to differ materially from those contemplated by any forward-looking statements, including, but not limited to, the risks associated with the followings; the Company's ability to remain profitable in a very competitive marketplace, which depends upon the Company's ability to differentiate its products and services from those of competitors; the Company's failure to realize assumptions and projections which may result in the need to record additional impairment charges; the effect of changes to the Company's distribution channels for its products and the failure of significant distributors of the Company's destribution channels for its products and the failure of significant distributors of the

Testimonials for Dentsply Sirona's products and services are received in various forms via a variety of submission methods. Individual results may vary. Dentsply Sirona does not claim, nor should anyone assume, that any individual experience recounted is typical or representative of what any other consumer might experience. Testimonials are not necessarily representative of what any other user may experience. The clinicians giving testimonials in the presentation have been compensated for use of their experiences.

# Non-GAAP Financial Measures

In addition to results determined in accordance with U.S. generally accepted accounting principles ("US GAAP") the Company provides certain measures in this presentation, described below, which are not calculated in accordance with US GAAP and therefore represent Non-GAAP measures. These Non-GAAP measures may differ from those used by other companies and should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with US GAAP. These Non-GAAP measures are used by the Company to measure its performance and may differ from those used by other companies. Management believes that these Non-GAAP measures are helpful as they provide a measure of the results of operations, and are frequently used by investors and analysts to evaluate the Company's performance exclusive of certain items that impact the comparability of results from period to period, and which may not be indicative of past or future performance of the Company.

The Company does not provide forward-looking estimates on a GAAP basis as certain information is not available and cannot be reasonably estimated.

# Today's Agenda

8:30 am	Welcome and Opening Remarks		10:40 am	Commercial Exc	ellence Panel
	Andrea Daley	VP, Investor Relations		Andrea Frohning Andrew Robinson	SVP, Chief Human Resources Officer SVP, North America RCO
	Transforming Dentistry			Bruce Peatey Gerry Campbell	GVP, APAC RCO GVP, EMEA RCO
	Simon Campion	President and Chief Executive Officer			
	Delivering Accelerated Growth			Driving Perform	
	Andreas Frank	EVP, Chief Business Officer			nain Transformation
	Connecting th	e Future of Dentistry		Tony Johnson	SVP, Chief Supply Chain Officer
	Max Milz	GVP, Connected Technology Solutions		Financial Review	
				Glenn Coleman	EVP, Chief Financial Officer
	Q&A Session			Q&A Session	
	Break			Closing Remarks	s
0:20 am	<b>KOL Panel</b>				
	Lauren Seymour Dr. Shivi Gupta Dr. Meena Barsou	VP of Sales, North America Commercial California Clinical Leader, Scripps Rock Dental Illinois Clinical Leader, Impressive Smiles	12:05 pm	Leadership Lunc	heon and Technology Tours





# Transforming Dentistry



Simon Campion President and Chief Executive Officer

November 9, 2023

# Key Messages

Dental is an attractive industry with DS **well-positioned for profitable growth** by executing on our clear strategy

Our transformation plans will shape a more durable, nimble and faster growing business over the long-term


Winning portfolio with sustainable competitive advantages including global scale and digital dentistry solutions


**New leadership team** driving a high-performance culture with focus on **execution**, **accountability and value creation** 



# Creating Value for All Stakeholders







III Includes dentists, technicians, hygienists and dental assistants that participated in clinical education courses in 202



# Dental: An Attractive and Evolving Market



# **Long-Term Macro Tailwinds**

- Positive demographic trends
- Increasing globalization
- Rising awareness of, and better access to, oral healthcare
- Continued aesthetic dental growth

30%+

Geriatric patients are edentulous<sup>(1)</sup>

8%+

Expected market growth of aesthetic dental<sup>(1)</sup>



# Integrated, Connected and

- Efficient digital workflows enabled by interoperable and connected technology
- Improved customer and patient experience
- Solutions to enhance collaboration between GPs, specialists, labs, DSOs and patients

50%

Practices using patient experience software<sup>(2)</sup>

**30%** Estimated global IOS adoption<sup>(3)</sup>



# **An Evolving Industry**

- Growing adoption of digital technologies
- Increasing DSO presence
- Increasing role for GP

40%

Dental practices will be part of DSOs within 5 years<sup>(3)</sup> 45% Global population affected by 1 or more

untreated oral diseases(4)

# Shifting Industry Dynamics Necessitate New and Innovative Solutions

GP: General Practitioner, DSO: Dental Support Organization

Source: Grand View Research, aesthetic dental services expected market growth CAGR '23 – '30

Source: Dentspiy Sirona estimates and J.P. Morgan North American Equity Reseat
 Source: World Health Organization



# Opportunity to Capture Share in Growing Segments



# Uniquely Positioned with a Winning Portfolio

LSD: Low-Single Digits, MSD: Mid-Single Digits Category data source: Internal estimates © CAGR through 2026E



# **Our Strategy**

Transform dentistry by digitalizing dental workflows, driving product and service innovation and delivering an exceptional customer and patient experience through an engaged and diverse workforce



ENHANCE & SUSTAIN PROFITABILITY

ACCELERATE ENTERPRISE DIGITALIZATION WIN IN ALIGNERS & IMPLANTS

CREATE HIGH PERFORMANCE CULTURE

**Enabled by the DS Operating Model** 

ONE TEAM | INNOVATION | DISCIPLINED EXECUTION



# The DS Operating Model



Plan | Process | Performance



# Winning as One Team ...



# **Ethics and Compliance**

- Tone from the top
- Code of Ethics and Business Conduct
- Speak up culture

# **Empowerment**

- Bold decision making
- Generation of new ideas

# Commitment

- Mission driven
- Organizational structure drives alignment, accountability and discipline
- Employee engagement and recognition

... To Build a High-Performance Culture

Ī



# A Sustainability Strategy Aligned to Our Company Strategy

# **SELECT 2022 ESG HIGHLIGHTS**

# **HEALTHY SMILES**



Empowered smiles



+7,000 Clinical education and training courses across 75 countries



+416,000 Dental professional clinical education course registrations<sup>(1)</sup>



25 million smiles



Top decile injury and illness prevention / avoidance rate

**2025 PRIORITY GOALS** 



Global gender parity



Gender pay parity





Net Zero carbon emissions (Scopes 1-3) by 2050





>15% Reduced water withdrawal intensity<sup>(2)</sup>

55%

Board member diversity<sup>(3)</sup>



>15% Reduced total GHG emissions intensity<sup>(2)</sup>

**HEALTHY BUSINESS** 


+2,600

Members participate in our 7 Employee Resource Groups





YoY decrease in recorded injuries or illness







# Achieving 25 million smiles by 2025



# **Empowering Women**

Making dentistry an inclusive industry by supporting women through various programs like Firstto50, Smart Integration Award, Partner of Women in DSO and She's Prime



# **Project 32**

Transforming access to dental care by providing endodontic treatment to people living in remote areas



# **Amazon Doctors**

Donating equipment and volunteering time to deliver oral health care in the Amazon






# **Smile Train**

Advancing the future of cleft care together. Through our donations we have supported more than 2,700 cleft surgeries since the launch of our partnership in 2021



DSO: Dental Support Organization

# New Leadership Focused on Execution, Accountability and Value Creation



Presenting Today

loined Dentsply Sirona within Last 2 Years



# Growing Through Innovation ...



# **Digitalization Focused on Customer Needs**

- Acceleration of digitally connected solutions
- Digitally mapped dental workflows
- Customizable and scalable

#### **Customer Centricity**

- Deeper and continuous customer needs assessment and involvement in product design
- Improving customer engagement and education
- Expanding partnership and engagement with DSOs

# **Product Quality and Patient Safety**

- Core to our philosophy of customer and patient centric
- Elevated role and visibility within DS
- Investments in processes and competencies

... To Transform Dentistry and Improve Customer Experience

DSO: Dental Support Organization



# Customer Perceptions Provide Portfolio Insights and Opportunity

**Voice-of-Customer Research** 

**2,000+** customers









# **Key Focus Areas for Strong Customer Advocacy**

- No meaningful gaps in product portfolio
- Ability to meet all key purchasing criteria (KPC)
- Sales and customer service performance
- Customer share of wallet
- Customer usage and future needs

NPS: Net Promoter Score
(1) At a master brand level

# **Voice-of-Customer Results**

NPS is At or Above Key Competitors<sup>(1)</sup>

Strong Customer Advocacy in Endo Files, Chairside Mill and 3D Printing

Cross-category Offerings that Provide Digital Integration and Convenience are Important



# Driving Disciplined Execution ...



# Integrated

- Enterprise first
- Infrastructure investments to drive efficiencies, improve customer experience and enable new business strategies

# **Efficient**

- Ongoing portfolio optimization
- Streamlining the organization; improving processes
- Simplifying the network

# Measurable

- Well-defined strategic and operational goals
- KPIs to monitor progress and drive performance
- Rigorous allocation of resources to high-return opportunities

... To Enhance Operational Excellence and Improve Business Performance

3

# Transforming the Business ...



... To Increase Efficiency and Effectiveness



# Execution x Transformation = Performance



+500 bps
Margin Expansion
2023E - 2026E


**\$3.00** 2026E Adj. EPS

- ✓ Higher growth trajectory
- Actions taken to reduce cost structure
- Focus investments on high-growth platforms and geographies
- New capital deployment strategy
- Drive improved organizational efficiency

Committed to Meaningful Improvement Over Next 3 Years and Beyond

Assumes non-recessionary, normalized macro environment, including patient traffic





# Accelerating Profitable Growth

Dentsply Sirona

Andreas Frank Executive Vice President, Chief Business Officer

November 9, 2023


# **Key Messages**

**Connected Portfolio – largest end-to-end dental platform** positioned for digital growth

**DS Core – cloud-enabled force multiplier** to connect clinical workflows and technology

Global Clinical Education – expansive and evolving programs to support customers

**Commercial Excellence** – focus on customer success and execution to deliver **sustained competitive advantage** 



Accelerating Profitable Growth with Enhanced Customer Experience

# Levers to Accelerate Profitable Growth Winning Portfolio Digitalization Customer Intimacy Clinical Education Customer Intimacy Disciplined Execution

Differentiated Customer Experience with Dentsply Sirona



# Comprehensive End-To-End Portfolio Across Served Markets

l Technology utions	Orthodontic and Implant Solutions		Essential Dental Solutions	Wellspect Healthcare	
MSD+ Target Growth <sup>(1)</sup>	\$0.7B   MSD 2022   Target Net Sales   Growth <sup>(1)</sup>	**So.3B 20%+ 2022	\$1.4B 2022 Net Sales  LSD Target Growth®	\$0.3B 2022 Net Sales  MSD+ Target Growth®	
		Key Product Cate	egories		
OS, Mill, Print) Centers and uments aging	Premium Implants Regenerative and Digital Services Lab Materials Value Implants	SureSmile Byte	Endodontics Restorative Preventive	Urology Enterology	
		Leading Market P	ositions		
#3 Treatment Centers and Instruments #2 Imaging	#4 Implants and Prosthetics	#3 Professional #2 DTC	#1 Endodontics #2 Restorative #1 Preventive	#2 Continence Care	
	WA	Y		1	
	MSD+ Target Growth®  OS, Mill, Print) Centers and uments aging  #3 Treatment Centers and	Implants  MSD+ Target Growth®  OS, Mill, Print) Centers and undensts aging  #3 Treatment Centers and Instruments  WHOD Target So.7B AMSD Target Growth®  Premium Implants Regenerative and Digital Services Lab Materials Value Implants  #4 Implants and Prosthetics	MSD+   Target Growth®   Solutions   Solutions   MSD+   Target Growth®   Solutions   Solu	Solutions   Solutions   Solutions   Solutions   Solutions	


# Wellspect Healthcare Business Overview



MSD: Mid-Single Digits
36 Sales by product category and sales by region pie charts represent 2022 Net Sales
Addressable market represents intermittent catheters and transanal irrigation (TAI) devices



## Wellspect Healthcare Growth Drivers



Accretive Growth and Margin Profile; Positioned to Gain Share

27 MSD = Mid-Single Digits, DTP = Direct-to-Patient



## DS Core as Force Multiplier for the Digital Dental Practice



Accretive Growth Through Connected Portfolio >45% of Revenue Today



## Connected Technology Solutions Business Overview



Leading Connected Portfolio for Efficient Digital Workflows






## Connected Technology Solutions Growth Drivers

# Key Initiatives Sales Growth Improve workflow efficiency MSD+ 3-Year CAGR Expand open, cloud-based DS Core platform

- Connect IOS and imaging installed base to DS Core
- Leverage CEREC leadership for milling and printing
- 5 Invest in operational and clinical AI



Enhanced Patient and Practice Outcomes with Practice Digitalization

30 MSD: Mid-Single Digits, IOS: Intraoral Scanner



## Implants and Prosthetics Solutions Business Overview

#### **Key Categories**

Premium Implants

#### Regenerative and Digital Services OSSIX, Atlantis








Lab Materials

Value Implants









#### Positioned to Enable the End-To-End Implant Workflow

MSD: Mid-Single Digits

Sales by product category and sales by region pie charts represent 2022 Net Sales

Market size source; management estimates: \*Depresents Implants, Biomaterials, and Lab Materials Addressable Market



## Implants and Prosthetics Solutions Growth Drivers



Customer Retention and New Customer Acquisition Globally

32 MSD: Mid-Single Digits



## Orthodontic Aligner Solutions Business Overview



DTC: Direct-to-Consumer

Sales by product category and sales by region pie charts represent 2022 Net Sales
Market size source: management estimates; "Represents Aligners Addressable Market




## Orthodontic Aligner Solutions Growth Drivers

#### **Key Initiatives**

## Improve customer acquisition and conversion rates (DTC and professional)

- 2 Continue global expansion and market penetration
- Increase manufacturing and treatment planning efficiency
- 4 Expand ancillary offerings to customers

#### Sales Growth



Scalable Infrastructure to Grow Share and Profitability

34 DTC: Direct-to-Consumer



#### Essential Dental Solutions Business Overview




LSD: Low-Single Digits
35 Sales by product category and sales by region pie charts represent 2022 Net Sales




### **Essential Dental Solutions Growth Drivers**

#### **Key Initiatives**

- Refine portfolio through strategic product life-cycle management and SKU optimization
- Pocus incremental innovation on procedural efficiency and clinical performance
- Improve cost and value proposition to compete across all segments and geographies
- Continue investing in clinical education and KOL network



**Sales Growth** 



#### Predictable and Efficient Clinical Performance

36 KOL: Key Opinion Leader, LSD: Low-Single Digits



#### Levers to Accelerate Profitable Growth

- Enable digital dental practice
- Drive focused innovation
- Manage product lifecycles

Winning Portfolio

- Leverage global footprint
- Enhance digital content
- Strengthen clinical network



Education



- Expand reach and channels
- Increase engagement
- Deliver customized offerings

**Key Value Drivers** 

Digitalization

**Customer Intimacy** 

**Disciplined Execution** 

Differentiated Customer Experience with Dentsply Sirona



## Focused Innovation Driving Return on Investment





Customer Centric Approach with Disciplined Execution

38 Pending FDA approval



## Efficiency Through Life-Cycle Management

#### **SKU Optimization**

- Initial focus on Endodontic and Restorative categories
- Less than 15% of products driving ~90% of revenue
- Many small SKUs add complexity with ~375 brands at <\$5M revenue</li>
- Robust data analytics to plan migration paths and maximize recapture rates
- Pilot approach to validate outcomes and gauge customer reception

#### **Future Opportunities**

- Fragmented geographic footprint creates further simplification opportunity
- Building capabilities to deploy for rigorous portfolio lifecycle management
- Funnel for next wave of opportunities identified for further evaluation



#### **Expected Outcomes**

#### \$30M

'24 - '26 targeted gross profit benefit

**Simplified Portfolio** 


**Optimized Footprint** 

**Improved Experience** 

Rigorous Portfolio Management Process



## World-Class Global Scale of DS Academy



Key Clinical Education Benefits

Developing relationships and engaging network of "digital" dentists

Reinforcing DS brand and industry leadership

Preparing next generation of dental practitioners

Customer Engagement with Continuous Learning Around the World

Map indicators represent the 20 DS Academies teaching digital dentistr



## Education Strengthens Global Clinical Network





KOL: Key Opinion Leader
41 PEERS: Platform for Exchange of Experience, Research and Science; PEERS was established by Dentsply Sirona in 200



## Global Commercial Footprint is an Important Differentiator





DSO: Dental Support Organization

10 Top 15 markets based on 2022 net sales



## Digital Platforms Drive Customer and Patient Engagement





- ~1M monthly unique visitors
- 40% without established dentist



- High repeat usage and ratings
- Al and human support providing remote care 7 days / week



- Currently in pilot phase
- Meeting patient needs for broader oral care

#### Expanding Access to Care and Life-Time Value of Customers



#### Committed to Win with DSOs



#### **DSO Needs**

#### **Practice-level**



#### **Enterprise-level**



Deliver patient outcome and satisfaction

Onboard and retain

qualified staff

Increase utilization

and profitability





Ensure security and regulatory compliance



Leverage scalable and customizable solutions

#### **Our Value Proposition**

#### ✓ Comprehensive Portfolio

- Cohesive and integrated solutions
   Support with clinical and operational workflows

#### ✓ Key Account Coverage

- Executive level commitment and local presenceTailored solutions with fewer touchpoints

#### ✓ Clinical Education

- Global infrastructure to support DSO training
- Tailored approach to meet specific needs

#### ✓ DS Core

- Additional enterprise-level capabilities
   Optionality with cloud-based ecosystem

Be Preferred DSO Partner to Realize Growth Potential

44 DSO: Dental Support Organization



#### Summary



Largest end-to-end connected portfolio in dental; accretive position in



DS Core uniquely positioned to connect clinical workflows and technology



Expansive and evolving global education footprint to support customers worldwide



Competitive advantage enabled through commercial excellence and execution





## Connecting the Future of Dentistry

Max Milz GVP, Connected Technology Solutions



November 9, 2023

### **Key Messages**

**Leading the industry forward** with **innovative solutions** that increase our addressable market and **connect the future of Dentistry** 

Enabling **better patient outcome** as well as **growth** and **efficiency** for dental practices

Driving **competitive differentiation** with full suite of proprietary and **industry-leading digital solutions**, enabled by our foundational cloud platform - DS Core

Integrating equipment, technology, and workflows to **enable high-value dental procedures** and **accelerate growth** 



## Dentists Across the World Desire Connected Technologies

I would expect from one company that all their devices connect very easily. We want predictable results.

User-friendly functions are incredibly important. I want to be able to focus on the treatment that I deliver.



**Dr. Chung** Australia





**Dr. Simpson**United Kingdom

Delivering Predictable Results Through Data and Connected Technology

Voice of Customer Research conducted in 2023 (n=2000+ customers, 3 key markets USA, DE, CN) indicated that cross-category offerings that provide digital integration and convenience are important



## Digital Technologies Drive Better Outcomes for Patients and Clinicians

#### 

Simplifying Dentistry Through Connected Technologies


Optimize IT spending

4

Collaborate with labs and dentists



#### Growth in High-Value Procedures and Need for Efficiency Gains Drive Adoption of Digital Technologies



- Practice needs to drive tech adoption
  - Greater efficiency (IOS, In-Office Milling, 3D Printing)
  - Growth with higher value / more technology procedures
- DS: recognized pioneer in digital dentistry

Continued Growth Opportunities as Technology Adoption Increases Across Dental Practices

CBCT: Cone Beam Computed Tomography, medical imaging technique used for implants Source: Dentsply Sirona estimates



## Simplifying Dentistry with Cloud-based Technology




#### DS Core is at the Heart of Our Connected Solutions




52 Note: not all capabilities are available today





53 IOS: Intraoral Scanner







Equipment management

Cloud-based media library

In-office milling and printing

## **Enhanced patient** consultation

Virtual simulations

Access to treatment services








## Enabling growth through case acceptance:

Flexible patient consultation on any screen and ability to share with patients











## We Closely Involve Our Customers in the DS Core Roadmap

#### **DS Core Innovation Day Across Specialties**

(October 2023, Zurich SW Engineering Hub)

- Key Opinion Leaders from APAC, EMEA, North America and Latin America
- Dental specialties (implants, ortho, endo, resto, GPs, labs)
- DS clinical experts, engineers and product managers
- Discussions on today's capabilities and future roadmap
- Continuously involvement of customers in new feature development and testing

#### **Key Opinion Leaders Here Today**

- Dr. Meena Barsoum
- Dr. Shivi Gupta





#### DS Core Target State: Achieving More with Less



DS Core: Creating the Integrated, Open Platform for Digital Dentistry

60 Destatis, 2023 (2) Customer Survey 2023



## Connecting the Industry's Largest Installed Base as Foundation for Digital Leadership




#### We Have the Right to Win in Digital Dentistry

Source: management estimates, internal data 61 Intraoral sensors and Extraoral 2D and 3D



## Milling and Printing: Combining Both Technologies in DS Core



#### DS has Leading Positions in Both Technologies

SOUTCE Hartnegement resumetes

1 Stiffe Industry update May 29th Deep Dive on In-Office 3D Printers. Current / Future Adoption Rates: Do you believe dental milling machines and 3D printers are complementary, or do you believe the

are cannibalistic (compete against each other)? Answers: 5% highly complementary, 28% somewhat complementary, 38% neither cannibalistic nor complementary, 5% somewhat
cannibalistic, 5% cannibalistic



### Summary



Connected Technology Solutions are the backbone of dental practice efficiency and growth



DS is a **leader in Connected Technology Solutions**(brand, installed base,



DS Core: integrating the biggest equipment installed base as foundation for digital leadership



Connected digital workflows as basis for growth in equipment and procedures









Key Opinion Leaders (KOL) Panel Discussion



November 9, 2023

# **Panelists**



VP of Sales, North America Commercial



**Dr. Shivi Gupta**California Clinical Leader, Resident
Faculty with CDOCS & international
lecturer with more than 19 years of
experience



**Dr. Meena Barsoum**Illinois Clinical Leader and recognized technology educator;
CAD/CAM & 3D CBCT user since 2010








Commercial Excellence Panel Discussion



November 9, 2023

# **Panelists**







# Enhancing Performance Through Global Supply Chain Transformation



Tony Johnson Senior Vice President, Chief Supply Chain Officer

November 9, 2023

# Key Messages

**Optimizing our manufacturing and distribution network** to operate more efficiently, cost effectively and profitably

**Building a long-term strategic** manufacturing and distribution **network roadmap** 

Driving tangible improvements through  ${\bf more\ efficient\ and\ standardized\ Global\ Supply\ Chain\ (GSC)\ business\ processes}$ 

Building strong partnerships between GSC, QARA and R&D



### GSC Improving Profitability and Customer Service

73 QARA: Quality Assurance and Regulatory Affairs



# Global Supply Chain Alignment to DS Strategic Objectives

### **Strategic Objective**

### **Global Supply Chain Alignment**



**Achieve Annual Growth** & Margin Commitments

- Back-order levels and make-to-order product lead times at targeted levels
- Achieving 2023 cost savings commitments



Enhance & Sustain Profitability

- Partnering with SKU Optimization team to drive cost out of the network
- Announced closure of 3 internal manufacturing locations and 1 distribution center



Accelerate Enterprise Digitalization

- Dedicated resources on ERP Modernization team
- Deployed Kinaxis Demand Planning solutions globally



- Balance insourcing / outsourcing opportunities
- Site consolidation to improve lead times



**Create High-Performance** Culture

- Dedicated senior level GSC Transformation team
- Increasing employee engagement through management system and town halls

74 GSC: Global Supply Chain



# Current Supply Chain Network




Manufacturing and Distribution Network with Global Presence and Opportunity

3

# Near-Term Network Optimization

### Desired Outcomes







### Non-Negotiables



Product Fulfillment



Regulatory Compliance

### **Approach**

- Dedicated cross-functional supply chain transformation team driving improved decision making and project execution
- Insource / outsource based on core Mfg competencies
- Consolidate sites to increase scale and leverage
- Optimize freight and distribution network

### **Execution**

- Announced closure of 3 Mfg sites (2 of 3 completed '23)
- Closed 1 distribution center
- Projects currently in execution and identified opportunities expected to deliver at least \$30M of GM expansion by '26

Deliver Near-Term Value and Efficiency Through Network Simplification

# Significant Opportunities for Current Plan and Beyond

### **Strategic Planning Process Underway**



Unlock value in our manufacturing and distribution network



Reduced costs and inventory levels, while shortening lead times and reducing GHG impact



### Manufacturing Goals

#### 1. Continued Site Consolidation

- Leverage SKU optimization workstream
- Reduce footprint by additional 15% 25%
- Reduce cost through leverage and efficiency

### 2. China for China

Increase locally manufactured products for China

#### 3. Balance Footprint

 Increase manufacturing presences in more cost-efficient markets

### **E** Distribution Goals

1. Design Network to Geographic Market Delivery Requirements Tailored to Product Categories

### 2. Optimize Hub and Spoke Distribution Network

- Drive inventory efficiency
- Improve transportation and freight efficiency

#### 3. Drive Automation

- NextGen ERP will unlock efficiencies
- Automate hub distribution centers



# Standardize and Leverage GSC Business Processes



### **Planning and Procurement Goals**

- Drive improved forecast accuracy through technology and process
- Reduce Days of Inventory on Hand (DIOH) by a minimum of 15 days by '26
- Driving proactive procurement process including:
  - Direct material savings
  - Supplier consolidation
  - Dual sourcing
- Execute indirect spending initiatives



- Centralized resources driving standardized processes and best practice across GSC
- Increase focus on both digital and physical automation across both mfg. and dist.
- Developing 3-year cost savings pipeline for all sites
- Execute ESG cost savings projects with a focus on:
  - Packaging
  - Energy, water and waste
  - Transportation

### Driving Continuous Improvement Through Disciplined Execution

78 GSC: Global Supply Chain



# Building Cross Functional Partnerships – GSC + QARA + R&D



### Culture

- Shifting from siloed approach in GSC, QARA and R&D
- Defining jointly owned 2024 KPIs
- Executing with continuous improvement mindset



### Organization

- GSC / QARA fully aligned direct staff to GBU model
- Structuring to enhance focus on supplier quality
- Creating capacity and expanding capabilities



### **Process**

- Embedding GSC + QARA earlier in New Product Development process
- Build GSC + QARA KPI in the innovation process

### Win as ONE Team

GSC: Global Supply Chain, QARA: Quality Assurance and Regulatory Aff



### Summary



Delivering **tangible near-term results** through early transformation actions



Developing **further cost reductions** through
additional mfg and
distribution footprint
opportunities



Unlocking
organizational capacity
and efficiency through
business practices
harmonization and ERP



Partnering cross functionally to accelerate growth and drive results





# Financial Review



Glenn Coleman Executive Vice President, Chief Financial Officer

November 9, 2023

# Key Messages

**Clear strategy to deliver above market sales growth** fueled by innovation and disciplined execution

Confident in path to \$3.00 adjusted EPS target by 2026

Double-digit adjusted EPS growth expected in 2024

**Increased capital deployment** with a plan to return ~75% of free cash flow to shareholders while maintaining low leverage



Building a Strong Foundation for Long-Term Outperformance

# Initial 2024 Projections

2023		2024	
	Current Outlook (as of 3Q23 Earnings Call)	<ul> <li>Double-digit adj.</li> <li>EPS growth</li> <li>expected in '24</li> </ul>	
Sales	\$3.90B - \$3.94B	<ul> <li>Adj. EBITDA margin</li> <li>+100 bps vs. 2023</li> </ul>	
Organic Growth	~1%	Commercial     investments in DSOs,     implants and aligners	
Adj. EBITDA Margin	>17%	deliver returns	1
		<ul> <li>Macro environment remains challenging</li> </ul>	0
Adj. EPS	\$1.80 - \$1.85		0

Moving from Year of Transition in '23 to Year of Inflection in '24



# **Enabling Performance and Driving Margin Improvement**

### Where We Were

- Siloed, inefficient organization
- ~30K SKUs in Endodontics/Restorative evaluated for SKU optimization
- 29 manufacturing sites; 73 distribution sites
- 14 ERP systems
- Suboptimal, inefficient, not integrated
- Inconsistent NPD process and launch cadence

### Where We Are Going ('24 - '26)

- Streamlined organization
- On track to deliver **\$200M+** in annualized savings
- ~12K SKUs, ~60% reduction
- Disciplined product lifecycle management process
- 3 announced plant closures; 1 DC consolidated
- 15% 25% incremental manufacturing footprint reduction
- 1 common ERP system
- Integrated infrastructure with increased automation
- Focused, effective NPD process

Transforming to Deliver +500 bps of EBITDA Margin Improvement Over Next 3 Years

DC: Distribution Center 84 NPD = New Product Developmen



### **ERP Transformation**

#### **Success Factors**

- Leverage best practices for limited risk
  - Not complete overhaul; ~40% of revenue already flows through next-gen platform
- Minimize customization
  - Robust design blueprint to reduce complexity
- Global standard processes
- Utilize phased approach
  - Deployments start 1H24
  - Multi-year project (3-4 years)
  - ~\$135M investment
- Maintain organizational change readiness

### **Benefits**

Improved customer experience

Informed decision making


Increased operational efficiency

**Enhanced compliance and controls** 

Easier M&A integration

ERP Modernization Critical Foundation to Long-Term Success






Assumes non-recessionary, normalized macro environment, including patient traffic



# Achieve 4% to 6% Organic Sales Growth






Improving Growth Through Innovation, Investment and Execution



# Multiple Levers Drive Margin Expansion

Restructuring Savings Global Operations Transformation





Meaningful Margin Expansion with Many Initiatives Underway or Nearing Completion

2026E

88


>17%

2023E

Organic Growth



# Building Blocks to \$3.00 Adj. EPS Target



**EPS Improvement Initiatives Underway** 



# Enhancing Free Cash Flow

### Long-Term Free Cash Flow






Free Cash Flow Targeted at ~100% Conversion by 2026

DIOH = Days of Inventory on Hand NPD = New Product Development



# Disciplined Capital Allocation Strategy



### **Go Forward Priorities**

# Reinvest for Growth and Efficiency (Capital Expenditures)

- High-return projects; ERP modernization
- Network and SKU simplification shifts from maintenance to growth capex

#### Pursue M&A

 Tuck-in acquisitions to enhance growth profile and do not require significant integration

#### Crow Dividond

**Opportunistic Share Repurchases** 

#### **Maintain Strong Balance Sheet**

Targeting leverage at or below 2.5x

Balanced Strategy with Planned Increase in Cash Returned to Shareholders

~75% of free cash flow

3

### M&A Framework



### **Financial Fit**

- Accretive sales growth and margin rates
- Accretive to EPS within 2 years
- ROIC > XRAY cost of capital



### **Strategic Fit**

- Addresses customer and market needs
- Capabilities enhancement
- Strengthens / differentiates portfolio




### **Feasibility Fit**

- Internal capabilities
- Location
- Competitive advantage

Focused on Strategic Tuck-in Opportunities without Major Integration Requirements

# Increasing Return of Cash to Shareholders



#### **Dividends**

- Expect dividend growth in-line with earnings growth through 2026E
- 12% dividend increase announced in 1Q23
- Attractive payout ratio relative to peers

### Share Repurchases

- Additional \$1B share repurchase authorization
- Variability on returning free cash flow to shareholders will depend on M&A activity
- Reduce share count while retaining M&A optionality

Returning ~75% of Free Cash Flow to Shareholders Over the 3-Year Period



# Delivering Profitable Growth...



### Well-Positioned in an Attractive Industry

- Broad portfolio >45% digitally-connected
- Trusted brands and strong positions across multiple categories
- Well-positioned to benefit from long-term dental industry trends
- Strategic objectives focus on high-growth categories



### Roadmap to Accelerate Profitable Growth

- Delivering a regular cadence of new products launches
- Gross margin expansion through SKU optimization and supply chain transformation
- SG&A optimization
- Clear strategy enabled by the DS Operating Model




### Disciplined Capital Allocation

- Healthy balance sheet and strong cash flow generation
- Dividend growth in line with earnings growth
- Improving free cash flow generation to enable 100% conversion

... to Maximize Total Shareholder Return







Closing Remarks



November 9, 2023

# Creating Value for Shareholders



Plan | Process | Performance

- **Dental is an attractive industry** with DS well-positioned for profitable growth by executing on clear strategy
- Transformation plans will shape a more durable, nimble and faster growing business over the long-term
- Winning portfolio with sustainable competitive advantages including global scale and digital dentistry solutions
- New leadership team driving a high-performance culture with focus on execution, accountability and value creation





### Non-GAAP Measures Definitions

Adjusted operating income is computed by excluding the following items from operating income (loss) as reported in accordance with US GAAP:

- justed operating in come is computed by excluding the following items from operating income (loss) as ordered in accordance with US CARA. Business combination related costs and fair value adjustments. These adjustments include costs related to consummating and integrating acquired businesses, as well as net gains and losses related to the disposed businesses. In addition, this category includes the post acqualism role of fair and in a fair and the season of the company of the control of the c
- (3) Goodwill and intangible asset impairments. These adjustments include charges related to goodwill and intangible asset impairments.

ted operating income margin is calculated by dividing adjusted gross profit by net sales.

Adjusted gross profit is computed by excluding from gross profit the impact any of the above adjustments that affect either sales or cost of sales.

Adjusted Net Income (Loss)
Adjusted net Income (loss) consists of net income (loss) as reported in accordance with US CAAP, adjusted to exclude the items identified above, as well as the related income tax impacts of those items. Additionally, net income is adjusted for other tax-related adjustments such as discrete adjustments to valuation allowances and other uncertain tax positions, final settlement of income tax audits, discrete tax items resulting from the implementation of restructuring initiatives and the windfall of shortfall relating to exercise of employee share-relating to prior periods.

These adjustments are irregular in filming, and the variability in amounts may not be indicative of past and future performance of the Company and therefore are excluded for comparability purposes.

In addition to the adjustments described above in arriving at adjusted net income, adjusted EBITDA is computed by further excluding any remaining interest expense, net, income tax expense, depreciation and amortization.

Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by net sales.

### Adjusted Earnings (Loss) Per Diluted Share

Adjusted earnings (loss) (EPS) per diluted share is computed by dividing adjusted earnings (loss) attributable to Dentsply Sirona shareholders by the diluted weighted average number of common shares outstanding.



Reconciliation of Non-GAAP Financial Measures Adjusted Free Cash Flow Conversion (unaudited)

A reconciliation of adjusted free cash flow conversion for the year ended December 31, 2022, is as follows:

(in millions, except percentages)	2022	
Net cash provided by operating activities	\$517	
Capital Expenditures	(149)	
Adjusted free cash flow	368	
Net loss attributable to Dentsply Sirona	(\$950)	
Amortization of Purchased Intangible Assets	153	
Restructuring Related Charges and Other Costs	144	
Goodwill and Intangible Asset Impairments	1,032	
Business Combination Related Costs and Fair Value Adjustments	7	
Fair Value and Credit Risk Adjustments	33	
Income Tax Related Adjustments	33	
Adjusted net income attributable to Dentsply Sirona	\$452	
Adjusted free cash flow conversion	81%	







**Simon Campion** President and Chief Executive Officer

Simon Campion joined Dentsply Sirona as President and Chief Executive Officer as well as a member of the Board of Directors in September 2022.

Mr. Campion previously served as Executive Vice President & President of the Interventional and Medical segments at BD (Becton, Dickinson and Company). When BD acquired C. R. Bard in 2017, he initially led the integration of the BD & Bard Surgery businesses into a single business unit and upon taking on the role of Executive Vice President & President of Interventional, a \$4.2 billion segment in 2021, led the broader segment through integration, and oversaw the global strategic, financial and innovation performance of the segment. Mr. Campion's leadership generated revenue growth at scale through expansion of the segment's organic innovation agenda and acceleration of its M&A objectives. Prior to BD's acquisition of C. R. Bard, Mr. Campion held several leadership roles across the C. R. Bard organization in the U.S. and Internationally, including President of the Surgery business unit. Previously he held marketing and R&D roles at Cook Medical and Boston Scientific.

 $Mr. \ Campion \ earned \ a \ Bachelor \ of Engineering \ and \ Ph.D. \ in \ Mechanical \ Engineering \ from \ the \ University \ of \ Limerick, \ Ireland \ and \ an \ MBA \ from \ the \ Open \ University \ in \ the \ UK.$ 



Glenn Coleman EVP, CFO

Glenn Coleman has served as Executive Vice President, Chief Financial Officer of the Company since September 2022.

Mr. Coleman previously served as Executive Vice President & Chief Operating Officer at Integra Lifesciences Holdings Corporation; a role held since 2019. As Chief Operating Officer, Mr. Coleman led operations and most of Integra's talent force, including clinical, R&D, manufacturing, and quality functions while also leading the international team. Mr. Coleman was previously Integra's Chief Financial Officer overseeing the finance department, including accounting and financial reporting, budgeting, internal audit, tax, treasury, investor relations, and information technology while also leading the international business.

Prior to Integra, Mr. Coleman spent 25 years in financial management positions with leading global businesses, including Curtiss-Wright Corporation and Alcatel-Lucent, and began his career at PricewaterhouseCoopers LLP.

Mr. Coleman earned a Bachelor of Science from Montclair State University and has been a CPA in New Jersey for more than 25 years.





Andreas Frank EVP, Chief Business Officer

Andreas Frank serves as EVP, Chief Business Officer at Dentsply Sirona.

Mr. Frank, who joined the company in April 2022, is a seasoned executive with broad background in driving business and portfolio growth, developing talent and strategic deployment and execution. He joined Dentsply Sirona from his position as President Front Line Care at Bakter. Previously, he spent 10 years at Hillrom, where he held leadership ostitions in the areas of Development, Strategy and Transformation to finally serve as Senior Vice President and President Front Line Care for over 3 years. From this position, he managed a global business with more than 2,500 employees in over 25 countries, and achieved high single digit growth through organic initiatives as well as M&A.

Prior to Hillrom, Mr. Frank served first as Vice President Business Development and then as Director Corporate Development at Danaher Corporation, where he focused on building out the dental platform which was subsequently spun out as a public company.

Mr. Frank holds a German Master's Degree in Economics and Business Administration, awarded by the Otto Beisheim School of Management in Koblenz (Germany), and an MBA from The University of Texas in Austin, McCombs School of Business.



Max Milz GVP, Connected Technology Solutions

Max Milz joined Dentsply Sirona in January 2021 to lead the company's clinical software and services business and to drive the transition to a new cloud platform. In his role as Group Vice President Connected Technology Solutions at Dentsply Sirona, he is responsible for the company's equipment, software, and cloud platform businesses globally, including Imaging, CAD/CAM and Treatment Centers.

Mr. Milz has strong leadership experience in high tech industries. Before joining Dentsply Sirona he was part of Siemens AG for 12 years. There he worked across the company's businesses with a focus on strategy and digital transformation, particularly in the healthcare and digital automation businesses. His last position was Senior Partner Management Consulting. During his time at Siemens, Mr. Milz worked across globe, thereof 5 years in China, reporting to the CEO of Siemens China.

Mr. Milz holds degrees from Harvard University, USA (Master in Public Policy) and the University of Cambridge, UK (BA/MA Cantab in Environment, Law and Economics).





Tony Johnson SVP, Chief Supply Chain Officer

Tony Johnson is the Chief Supply Chain Officer of Dentsply Sirona.

Before joining Dentsply Sirona in November 2022, Mr. Johnson served as the President of Global Products and Supply Chain at Cardinal Health where he led upstream product marketing, research and development, and the medical segment global supply chain.

Prior to that, he was Senior Vice President of Operations at Becton Dickinson (BD) / CR Bard where he was responsible for their Interventional Segment and spent 25 years with Baxter International where he held positions leading operations both in the United States and internationally. He is a seasoned operations executive with 30 years of global experience across engineering, manufacturing, supply chain and procurement in the medical device business with a strong history of delivering results. His successful career path includes roles as an executive leadership / corporate officer and in quality system leadership, lean operating system implementation, new product development, global and regional leadership and multi-site management.

Mr. Johnson received his bachelor's degree in industrial engineering from the University of Arkansas.



Lauren Seymour VP of Sales, North America Commercial

Lauren Seymour joined Dentsply Sirona in December 2020 and currently leads all product sales for North America. She is focused on providing digital workflow solutions to dental practices across the U.S. to enhance the patient experience, increase practice efficiencies and expand their suite of offerings for growth.

Previously, Ms. Seymour was with Philips Healthcare where she was the U.S. Market Leader for their Therapeutic Care business. During her over 20-year tenure at Philips, she managed various North American sales channels, including Diagnostic Cardiology, Hospital Respiration Care and Emergency Care and Resuscitation. She worked within both direct and inferet channels to drive substantial business growth. Her leadership skills were recognized in 2018 with the CEO Leadership Award as well as the Philips Inspirational Leadership Award in 2019.

Ms. Seymour is on the Advisory Board of WinDSO (Women in Dental Support Organizations). WinDSO is committed to serve as a platform to advance and promote bright women leaders across the DSO space.

 $Lauren\ graduated\ from\ Spring\ Hill\ College\ in\ Mobile,\ Alabama,\ with\ a\ Bachelor\ of\ Business\ Administration.$ 





Andrea Frohning SVP, Chief Human Resources Officer

Andrea Frohning joined Dentsply Sirona as Senior Vice President, Chief Human Resources Officer in July 2023.

She has over twenty-five years of experience in diverse business environments and industries including consumer products, industrial manufacturing, healthcare, distribution and financial services.

Before joining Dentsply Sirona, Ms. Frohning served as Chief Human Resources Officer of Premier Incorporated. Prior to Premier she was the Chief Human Resources Officer at Patterson Dental between 2018 and February 2023 and at Snyder's-Lance between 2016 and 2018. Ms. Frohning also served as Vice President Human Resources at Crane Co. from 2013 to 2016. Previously, she held various leadership positions at Hubbell, General Electric and Pepsi Bottling Group.

Ms. Frohning holds a Master's Degree in Human Resources and Industrial Relations as well as a Bachelor of Science in Development and Family Studies from the University of Illinois.



Andrew Robinson SVP, North America RCO

Andrew Robinson is Senior Vice President, North America Regional Commercial Organization (RCO) at Dentsply Sirona

A globally experienced executive with a customer-first, growth-oriented mindset, he has a long and distinguished track record of delivering outstanding results in complex environments and fostering a culture of engagement and accountability.

Mr. Robinson joined Dentsply Sirona in March 2022 from the medical company, Coloplast, where he served as Senior Vice President for Emerging Markets. Previously, he was Vice President, Surgical for the APAC region of Alcon as well as Vice President and GM for Stryker Corporation's Medical and Surgical Equipment business in Tokyo.

Earlier in his career, he held positions of increasing responsibility in Sales and Marketing, starting as a sales representative and progressing through sales training, management, and global product management.

Mr. Robinson, a United States Air Force veteran, earned an MBA in Global Strategic Management and Marketing from the University of Wisconsin and holds a bachelor's degree in Atmospheric Sciences from the Ohio State University.

in new product development.



Bruce Peatey

Bruce Peatey is the Group Vice President for the Asia Pacific (APAC) RCO, leading Japan, China, Hong Kong, Taiwan, South Korea, Australia, New Zealand, Philippines, Southeast Asia, and India. Mr. Peatey joined Dentsply Sirona in 2022 and brings more than 25 years of experience to his current role.

Prior to joining Dentsply Sirona, Mr. Peatey was the Vice President Regional Business Unit, Connected Health & Commercial at Excellence Baxter International APAC. Prior to that he worked with Hillrom as Vice President & General Manager Australia & New Zealand. Mr. Peatey is a senior healthcare industry commercial leader, experienced in large medical device and entrepreneurial biotechnology companies. His successful career history is based on strong competency in sales, strategy, marketing, and the knowledge of the Asia Pacific region.

He received his bachelor's degree in medical laboratory science from Queensland University of Technology and has an MBA from Griffith University, both in Brisbane, Australia.



Gerry Campbell GVP, EMEA RCO

Gerry Campbell joined Dentsply Sirona 2007 as Vice President and General Manager of the DENTSPLY UK and Ireland business. Mr. Campbell became Group Vice President Dentsply Sirona Northern EMEA in January 2019 and held other Vice President and General Manager roles at Dentsply Sirona before that. He became Group Vice President Commercial EMEA October 2020.

In his role, Mr. Campbell is leading the Northern RCO and have the following RCOs report to him: RCO DACH, RCO Southern, RCO Eastern.

Prior to joining Dentsply Sirona, Mr. Campbell had a 21-year career with Cookson Group plc, 14 years in EMEA manufacturing leadership roles and 7 years in global marketing. During this period, he gained experiences in six sigma, manufacturing processes & restructuring and

 $Mr. \ Campbell's \ undergraduate \ studies \ were \ in \ Mechanical \ Engineering \ at \ the \ University \ of \ Strathclyde, \ and \ he \ received \ his \ MBA \ from \ Glasgow \ Caledonian \ University.$ 

He is based at Dentsply Sirona's UK&I headquarters in Weybridge.





Rich Rosenzweig SVP, Corporate Development, General Counsel & Secretary

Rich Rosenzweig is the Senior Vice President, Corporate Development, General Counsel and Secretary of the Company and he serves as a member of the company's Management Committee.

Most recently, he served as Senior Vice President, General Counsel & Secretary at AngioDynamics where he led the legal department including compliance and served as Secretary to the Board for this publicly traded medical device company. Previously, he held several roles during his more than ten years at C. R. Bard Inc., including serving as Vice President, Law & Assistant Secretary, and being a Member of the Corporate Management Committee. Other previous experiences include General Counsel roles at other public companies and a leading role at Johnson & Johnson.

He is a member of the Director's Leadership Council at Rutgers Biomedical and Health Sciences and has served as a member of the Rutgers Cancer Institute of New Jersey Director's Leadership Counsel for 15 years.

Mr. Rosenzweig earned his law degree from Boston University School of Law and holds a Bachelor of Arts, Psychology, from Brandeis University



Emily Miner SVP, Chief Quality

Emily P. Miner joined Dentsply Sirona as Senior Vice President, Chief Quality Officer in May 2023.

Before joining Dentsply Sirona, Ms. Miner served as Senior Vice President, Global Quality and Regulatory, at Terumo Cardiovascular ("TCV") since 2018. In addition to her core Quality & Regulatory responsibilities there, she was also accountable for Quality and Regulatory business development activities, acquisition due diligence, and facility optimization/tech transfer activities. Prior to TCV, she was with PwC PRTM Management Consultants, Hospira, and Boston Scientific.

Ms. Miner is a proven strategic leader with more than 15 years of experience in Quality and Regulatory leadership in the medical device and pharmaceutical industries. Her experience in all elements of Quality and Regulatory management includes a Consent Decree remediation, several general quality system remediations, extensive global regulatory inspection preparation and management, stage gate development projects, strategic program management, and global quality operations.

Ms. Miner holds a Bachelor of Science in Bioengineering from the University of Pittsburgh and a Master of Engineering Management from Duke University.





Rodrigo Canelhas GVP, LATAM RCO

Rodrigo Canelhas joined Dentsply Sirona in 2010 where he currently serves as Group Vice President for the LATAM RCO, including 20 countries.

Mr. Canelhas boasts a 24-year career in management roles in startups and leading multinationals from the health care, consumer goods and telecom industries such as Ambev (AB Inbev), Souza Cruz (BAT), Danone and Telefonica.

He is responsible for the start-up of a Sirona subsidiary in Brazil from scratch. Under his leadership and innovative customer-centric B2C approach, the subsidiary reached a consolidated breakeven in its first 12 months and increased business by 1000% in just three years. He also led the integration of Dentsply, Sirona and VIPI in Brazil and in the whole LATAM. Our LATAM RCO has grown revenue at 9% CAGR since 2017.

Before joining Dentsply Sirona, he was responsible for managing six product lines and a distribution network with eight distributors throughout Brazil at Stryker. Mr. Canelhas and his team led an increase in sales of more than 50% CAGR from 2006 to 2009.

Mr. Canelhas holds a degree in Advertising and Marketing and an MBA from ESPM (Higher School of Advertising and Marketing). He also specialized in Business Strategy at the University of São Paulo and in Business Management at Fundação Dom Cabral. In 2019, he participated in the EIP, Exponential Innovation Program, at Singularity University in California, USA.



Erania Brackett SVP, Orthodontic Aligner Solutions & Customer Experience, and Head of Sustainability

Erania Brackett is currently Senior Vice President, Orthodontic Aligner Solutions & Customer Experience, and Head of Sustainability for Dentsply Sirona. Ms. Brackett has served in that position since April 2023.

Ms. Brackett is responsible for leading Dentsply Sirona's efforts to enhance the customer experience across multiple areas, including brand management, pricing, clinical education, digital marketing, and key opinion leader governance and programs. Additionally, she is responsible for the rapidly growing orthodontic aligner solutions business, including DTC-focused Byte brand and B2B-focused Suresmile brand. Prior to that time, Ms. Brackett served as Senior Vice President and Chief Marketing Officer for Dentsply Sirona from August 2021 to March 2023.

Prior to Dentsply Sirona, she worked at Medtronic, as Vice President, Global Commercial Marketing, Patient Management, Cardiac Rhythm & Heart Failure division and previously as Senior Director, Patient Management Global Commercial Marketing. She began as Senior Director, Global Hardware and Software Operations. Before joining Medtronic, she worked at GE Healthcare for 15 years and held various commercial and operational leadership roles.

Ms. Brackett holds a bachelor's degree in Chemical Engineering from Tuskegee University and is pursuing an Executive MBA at Emory University's Goizueta School of Business.





Andrea Daley
VP, Investor Relations

Andrea Daley is the Vice President, Investor Relations for Dentsply Sirona. Ms. Daley joined Dentsply Sirona in 2021 and brings nearly 20 years of healthcare industry and corporate finance experience to her current role.

Before joining Dentsply Sirona, she worked at McKesson Corporation, as Senior Director, Financial Planning & Analysis for the CoverMyMeds business. As a financial business partner, she helped drive business growth and profitability while also leading several integration initiatives. Prior to McKesson, Ms. Daley spent 16 years at Cardinal Health in a variety of financial, strategic, and operational roles. She served in several financial planning & analysis roles across different businesses as well as enterprise level finance and accounting roles. In her time at Cardinal Health, Ms. Daley also had experience stepping into leadership roles outside of finance to drive transformational initiatives and support commercial teams.

Ms. Daley holds a bachelor's degree in Finance and Business Economics from Ohio University and is a member of NIRI, the National Investor Relations Institute.



# **Key Opinion Leaders**



Dr. Shivi Gupta
Clinical Leader
SCRIPPS ROCK

Dr. Shivi Gupta owns a practice in San Diego, California that is focused on CAD / CAM and CBCT technology.

She completed advanced education in general dentistry residency at The University of Texas Health Science Center in San Antonio and graduated from dental school at the University of Manitoba, Canada. Over the course of her 20 years in practice, her passion for digital technology has led her to use CAD / CAM to its fullest potential for crown bridges, implants, smile design appliances, and Suresmile clear aligners. Dr. Gupta is a Resident Faculty with CDOCS, a Clinical Leader for Imagen Dental Partners, a KOL for Dentsply Sirona, a Beta Tester for Dentsply Sirona, a Field Tester for various dental companies, and an advanced trainer for Patterson in the San Diego area.

She has lectured internationally on CAD / CAM and digital dentistry.



Dr. Meena Barsoum



110

Dr. Meena Barsoum practices general and implant dentistry in Chicago, IL, and serves as Resident Faculty in the CAD / CAM division at CDOCS. Dr. Barsoum has been a CAD / CAM and 3D CBCT user for over a decade and currently trains doctors worldwide on CEREC and guided implant surgery.

He started Impressive Smiles in 2010 and currently maintains a thriving practice centered around CAD / CAM, implants, and digital dentistry. Dr. Barsoum also serves as Clinical Leader for Imagen Dental Partners, the nation's fastest-growing dental partnership organization.

Dr. Barsoum has two young boys and enjoys boating on Lake Michigan. He is also currently completing an MBA program at the University of Illinois.

